| 2026-08-13 | Press release | Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights |
| 2026-08-11 | Presentation | Corporate Presentation - August 2026 |
| 2026-08-03 | Press release | Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 |
| 2026-08-03 | Press release | Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-29 | Press release | Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston |
| 2026-07-08 | Press release | Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-01 | Press release | Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-30 | Press release | Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN |
| 2026-06-25 | Press release | Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer |
| 2026-06-02 | Press release | Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Impro |
| 2026-06-01 | Press release | Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-15 | Presentation | AUA Investor Call Presentation |
| 2026-05-15 | Press release | Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of |
| 2026-05-13 | Press release | Candel Therapeutics to Present at Upcoming Investor Conferences |
| 2026-05-04 | Press release | Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglat |
| 2026-04-29 | Press release | Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene |
| 2026-03-17 | Press release | Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced |
| 2026-03-09 | Press release | Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenov |
| 2026-02-24 | Press release | Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston |
| 2026-02-11 | Press release | Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit |
| 2025-12-05 | Presentation | December 2025 R&D Day Corporate Presentation |
| 2025-11-17 | Press release | Candel Therapeutics to Host Virtual R&D Event on December 5, 2025 |
| 2025-06-05 | Presentation | Jefferies Global Healthcare Conference Presentation |
| 2022-12-06 | Presentation | 2022 Virtual Research & Development Day Presentation |
| Press release | Candel Therapeutics to present at upcoming Jefferies Virtual Healthcare Conference |
| Press release | Candel Therapeutics’ CAN-3110 Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Onco |
| Press release | Candel Therapeutics names Carrie S. Cox as Chairman of its Board of Directors |
| Press release | Candel Therapeutics Completes Enrollment in Phase 1 Clinical Trial of CAN-2409 in Combination with Opdivo® (nivolumab) f |
| Press release | Candel Therapeutics appoints Diem Nguyen, PH.D., M.B.A., to its Board of Directors |
| Press release | Candel Therapeutics Appoints Chris Matheny, PharmD, Ph.D., as Vice President, Development Leader |
| Press release | Candel Therapeutics Announces Formation of New Research Advisory Board Comprised of Multiple Prominent Scientists and Cl |